Agenus’ (AGEN) “Neutral” Rating Reaffirmed at HC Wainwright

HC Wainwright reaffirmed their neutral rating on shares of Agenus (NASDAQ:AGEN) in a research note issued to investors on Friday morning,Benzinga reports. HC Wainwright currently has a $7.00 price target on the biotechnology company’s stock.

A number of other equities research analysts have also commented on AGEN. B. Riley dropped their price target on Agenus from $42.00 to $18.00 and set a “buy” rating on the stock in a research report on Wednesday, August 14th. StockNews.com lowered shares of Agenus from a “hold” rating to a “sell” rating in a research note on Monday, August 12th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and one has issued a buy rating to the company’s stock. According to data from MarketBeat, Agenus presently has an average rating of “Hold” and a consensus price target of $10.00.

Agenus Stock Down 2.0 %

AGEN opened at $3.42 on Friday. The stock has a market cap of $80.23 million, a P/E ratio of -0.30 and a beta of 1.39. Agenus has a 12 month low of $2.50 and a 12 month high of $19.69. The company has a fifty day simple moving average of $4.20 and a 200 day simple moving average of $8.13.

Institutional Investors Weigh In On Agenus

Institutional investors have recently bought and sold shares of the company. Point72 DIFC Ltd acquired a new stake in shares of Agenus in the second quarter valued at approximately $51,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in Agenus in the 2nd quarter valued at $106,000. HighTower Advisors LLC lifted its position in Agenus by 46.1% during the 3rd quarter. HighTower Advisors LLC now owns 23,851 shares of the biotechnology company’s stock worth $122,000 after buying an additional 7,530 shares in the last quarter. Exchange Traded Concepts LLC boosted its stake in shares of Agenus by 52.0% during the 3rd quarter. Exchange Traded Concepts LLC now owns 27,543 shares of the biotechnology company’s stock worth $151,000 after buying an additional 9,422 shares during the last quarter. Finally, State Street Corp boosted its stake in shares of Agenus by 2.1% during the 3rd quarter. State Street Corp now owns 467,771 shares of the biotechnology company’s stock worth $2,563,000 after buying an additional 9,731 shares during the last quarter. Institutional investors own 61.46% of the company’s stock.

About Agenus

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.